Sunday 18 October 2026
Export CYAD’s income statement to Excel — free account
Celyad SA
CYAD Healthcare Biotechnology
Celyad SA’s revenue for fiscal 2025 (year ended December 2025) was $23,800.00, down 88.2% from fiscal 2024.
Follow CYAD
| Older periods | Jun '23 | Jun '24 | Jun '25 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
1.16 | 2.99 | 0.40 | 0.88 | |
Current Ratio |
1.26 | 3.59 | 0.66 | 0.94 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
2.88% | 6.49% | 13.23% | 0.00% | |
Debt/Equity |
0.34 | 0.26 | (0.24) | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | — | |
Capex/Depreciation |
2.52 | 0.00 | 0.00 | — | |
Intangible Assets out of Total Assets |
0.05 | 0.04 | 0.06 | 0.01 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | |
Free Cash Flow Yield |
— | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | — | |
Capex per Share |
0.00 | 0.00 | — | — | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | — | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(7.99) | (3.05) | (3.72) | — | |
Working Capital |
1.75 | 6.73 | (1.43) | (0.07) | |
Capital Expenditures |
1.09 | (0.13) | — | — | |
Net Current Asset Value |
(3.78) | (0.99) | (7.20) | (0.23) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
2.47 | 2.42 | 2.30 | 1.07 | |
Average Payables |
5.62 | 3.66 | 3.72 | 2.65 | |
Average Assets |
52.06 | 45.75 | 36.83 | 11.84 | |
Average Common Equity |
15.90 | 22.23 | 186.45 | (5.82) |
Columns are period end dates · fundamentals updated 14 Oct 2026